The Global Multiple Myeloma Market size is expected to reach $37.5 billion by 2029, rising at a market growth of 9.8% CAGR during the forecast period.
Multiple myeloma or plasma cell cancer is a disease. The immune system is significantly dependent on healthy plasma cells, which are located in the bone marrow. In order to combat infections and other diseases, the immune system is composed of various cell types. T cells and B cells are two of the most common types of lymphocytes (lymph cells) in the immune system. The lymph nodes, bone marrow, intestines, and circulation are just a few of the organs where lymphocytes can be found.
B cells develop into plasma cells due to the immune system's response to an infection. Antibodies, also known as immunoglobulins, are produced by plasma cells and aid the body's defense against pathogens. Bone marrow contains the majority of plasma cells. Soft tissue found inside bones is called bone marrow. Other blood cells, including red, white, and platelets, are also found in the normal bone marrow and plasma cells.
Multiple myeloma is the term used to describe plasma cells that have developed malignancy and are growing uncontrollably. Monoclonal immunoglobulin, or M-protein, M-spike, or paraprotein, is an aberrant protein (antibody) produced by plasma cells. Immunoglobulins made by healthy plasma cells can recognize and eliminate germs, which is helpful in the fight against infections.
However, cancerous plasma cells gather in the bone marrow of patients with multiple myeloma and destroy healthy blood cells. As a result, the body produces paraproteins, aberrant proteins that can accumulate and harm tissues and organs. Multiple myeloma has several side effects, including frequent infections, anemia, bone pain, and renal problems. Targeted therapy, chemotherapy, radiation therapy, and stem cell transplantation are available as alternatives for treatment.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Novartis AG, Johnson & Johnson, and Pfizer, Inc. are the forerunners in the Multiple Myeloma Market. Companies such as Amgen, Inc., Sanofi S.A., and Bristol Myers Squibb Company are some of the key innovators in Multiple Myeloma Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Multiple myeloma or plasma cell cancer is a disease. The immune system is significantly dependent on healthy plasma cells, which are located in the bone marrow. In order to combat infections and other diseases, the immune system is composed of various cell types. T cells and B cells are two of the most common types of lymphocytes (lymph cells) in the immune system. The lymph nodes, bone marrow, intestines, and circulation are just a few of the organs where lymphocytes can be found.
B cells develop into plasma cells due to the immune system's response to an infection. Antibodies, also known as immunoglobulins, are produced by plasma cells and aid the body's defense against pathogens. Bone marrow contains the majority of plasma cells. Soft tissue found inside bones is called bone marrow. Other blood cells, including red, white, and platelets, are also found in the normal bone marrow and plasma cells.
Multiple myeloma is the term used to describe plasma cells that have developed malignancy and are growing uncontrollably. Monoclonal immunoglobulin, or M-protein, M-spike, or paraprotein, is an aberrant protein (antibody) produced by plasma cells. Immunoglobulins made by healthy plasma cells can recognize and eliminate germs, which is helpful in the fight against infections.
However, cancerous plasma cells gather in the bone marrow of patients with multiple myeloma and destroy healthy blood cells. As a result, the body produces paraproteins, aberrant proteins that can accumulate and harm tissues and organs. Multiple myeloma has several side effects, including frequent infections, anemia, bone pain, and renal problems. Targeted therapy, chemotherapy, radiation therapy, and stem cell transplantation are available as alternatives for treatment.
COVID-19 Impact Analysis
Since R&D operations were substantially hampered by the pandemic, developing novel medicines and treatments for multiple myeloma also slowed considerably. Moreover, the Blood Cancer Journal reported in December 2021 that fewer new instances of multiple myeloma were identified in 2020 in comparison with 2019 and that the survival rate for those cases declined concurrently. Patients with multiple myeloma had a higher mortality rate and COVID-19 infection risk in 2020. Therefore, the pandemic had a detrimental effect on the multiple myeloma market.Market Growth Factors
Increasing government support initiatives worldwide
Along with care practices, governments and organizations are also extending support for other current problems in provider relations include fee schedules & reimbursement, sites of care, route of drug administration, and politics as well as other network issues. These problems are pushing oncology practices into more payer-provider collaborative initiatives, including accepting patient-care medical homes, where primary care doctors coordinate care with experts and other specialists and creating affordable oncology healthcare institutions in both the commercial and Medicare/Medicaid spaces. Hence, the increasing support of governments is projected to increase demand for treatments or medications for multiple myeloma, thereby fueling market expansion.Rising cases of multiple myeloma worldwide
The rising incidence of several types of blood malignancies, including multiple myeloma, is one of the major market-driving factors. Although MM is regarded as a more uncommon cancer kind, there are a sizable number of cases of cancer worldwide, and the demand for effective and cutting-edge therapies is rising. Patients frequently experience better and more favorable clinical results when effective and cutting-edge therapies are administered. This is crucial because current trends point to an increase in the prevalence of MM around the globe. In addition, as a result of ongoing R&D, treatment has advanced, necessitating more complex medicines to improve prognosis.Market Restraining Factors
Lack of permanent solutions and side effects of many existing treatments
Common side effects of Kyprolis include fatigue, a low blood cell count and blood platelet levels, diarrhea, constipation, nausea, shortness of breath, fever, swelling of the extremities, upper respiratory tract infection, bronchitis, and pneumonia. Additionally, certain side effects of the drug include low blood potassium, high blood sugar, low blood calcium, muscle spasms, numbness and tingling in the extremities, and high blood pressure. In addition, radiation therapy can cause adverse effects such as fatigue, irritation of the skin, nausea, diarrhea, loss of hair in the treatment area, infertility, higher risk of infection, loss of appetite, increased risk of subsequent cancer, and harm to organs located near the treatment area.Drug Type Outlook
Based on drug type, the multiple myeloma market is categorized into chemotherapy, protease inhibitors, monoclonal antibody, and others. The monoclonal antibodies segment procured a considerable growth rate in the multiple myeloma market in 2022. The therapeutic options for multiple myeloma have radically changed due to the recent introduction of monoclonal antibodies (mAbs). The effectiveness of elotuzumab and daratumumab in relapsed/refractory patients has sparked much interest in mAbs for this condition.
End-user Outlook
On the basis of end user, the multiple myeloma market is divided into hospitals, clinics, and others. The hospitals segment acquired the largest revenue share in the multiple myeloma market in 2022. The hospital segment is growing due to factors including an increase in patient admissions, a rise in the prevalence of multiple myeloma, and the availability of qualified medical staff in these facilities that enable improved patient services. The fact that the medications used in treatment can be routinely prescribed and given in hospital settings accounts for a significant portion of this segment's dominance.Disease Type Outlook
Based on disease type, the multiple myeloma market is segmented into active multiple myeloma and smoldering multiple myeloma. The smoldering multiple myeloma segment garnered a remarkable growth rate in the multiple myeloma market in 2022. The growth of the segment is owed to the increasing awareness of the disease. It may take years for smoldering multiple myeloma to develop into an active form. As a result, some individuals with this syndrome never experience active MM. Healthcare professionals’ control SMM by watching for symptoms that it's turning into active multiple myeloma.Regional Outlook
On the basis of region, the multiple myeloma market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the multiple myeloma market in 2022. Due to the strong presence of key competitors and the rise in multiple myeloma drug launches and product approvals, the North American multiple myeloma market is predicted to expand considerably over the forecast period. Moreover, the market is anticipated to develop because of the rising prevalence of multiple myeloma. For instance, the American Cancer Society forecasted that by 2023, 35,730 incidences of multiple myeloma would have been discovered in the United States.The Cardinal Matrix - Multiple Myeloma Market Competition Analysis
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Novartis AG, Johnson & Johnson, and Pfizer, Inc. are the forerunners in the Multiple Myeloma Market. Companies such as Amgen, Inc., Sanofi S.A., and Bristol Myers Squibb Company are some of the key innovators in Multiple Myeloma Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Recent Strategies Deployed in Multiple Myeloma Market
Partnerships, Collaborations and Agreements:
- Mar-2022: Sanofi came into collaboration with Blackstone Life Sciences, a US-based private equity firm focused on investing in pharmaceutical, life science, and medical research companies. The collaboration involves the private equity firm contributing up to 300 million euros to advance studies and clinical development programs for the development and delivery of the anti-CD38 antibody Sarclisa focused on treating patients with multiple myeloma.
- Jan-2020: Sanofi partnered with Sebia, a France-based provider of clinical protein electrophoresis equipment. The partnership focuses on co-developing treatment for multiple myeloma. The agreement includes Sebia developing in vitro diagnostic (IVD) tests and acting as its supplier.
Product Launches and Product Expansions:
- Mar-2023: Teva and Natco together launched extra strengths for the generic version of Revlimid. The medicine is intended to be used by adult patients for the cure of multiple myeloma, specific myelodysplastic syndromes, and mantle cell lymphoma. The added strengths reflect the company's devotion to making generic drugs accessible to patients who need them.
- Feb-2022: Sandoz, part of Novartis introduced lenalidomide, a generic oncology medicine. The medicine is intended for various haemato-oncology conditions and is available in the form of hard capsules. Lenalidomide is a cost-saving treatment, thereby increasing the treatment's accessibility amongst patients.
- Dec-2021: Novartis introduced T-Charge, a CAR-T platform that would act as a base for multiple investigational CAR-T cell therapies. The T-Charge eradicates the need for extended culture time outside the body (ex-vivo), as it primarily happens within a patient's body.
Acquisitions and Mergers:
- Dec-2022: Johnson & Johnson took over Abiomed, a US-based medical device technology company. The addition of Abiomed advances the acquiring company's MedTech business division, by providing innovational medical technologies. Further, the acquisition broadens Johnson & Johnson's cardiovascular product offerings.
- Dec-2021: Baxter acquired Hillrom, a US-based medical device company. The acquisition advances the company's mission to transform healthcare and patient care.
- Nov-2021: Pfizer acquired Trillium Therapeutics, a Canada-based clinical-stage immuno-oncology company. The acquisition strengthens the acquiring company's devotion to seeking scientific breakthroughs. Further, the addition of Trillium expands Pfizer's hematology product offerings.
- Oct-2021: Amgen completed the acquisition of Teneobio, a US-based biotechnology company. The acquisition of Teneobio broadens the acquiring company's skills and further accelerates its aim to design, build and bring innovations to the markets to better serve their patients. Further, the addition of Teneobio's proprietary bispecific and multispecific antibody technologies perfectly complements Amgen's BiTE platform and its already existing antibody capabilities.
Trials and Approvals:
- Oct-2022: The US FDA issued clearance for Johnson & Johnson’s Tecvayli, a BCMA-targeted bispecific drug intended for treating patients with refractory or relapsed multiple myeloma. As the conditions to be met to use the recently approved drug, patients must have undergone a minimum of four lines of therapy.
- Jan-2022: Bristol Myers Squibb received approval for Abecma in Japan. Abecma is a CAR T therapy intended for adult patients with refractory or relapsed (R/R) multiple myeloma. The adult patient should have already received a minimum of three therapies and should have experienced disease progression on the last therapy. Further, the approval demonstrates the company's devotion to catering to the unmet medical needs in Japan.
- Dec-2021: U.S. Food and Drug Administration (FDA) approved Amgen's expansion of KYPROLIS to use it in combination with DARZALEX FASPRO, and dexamethasone. The new combination is intended for adult patients with refractory or relapsed multiple myeloma, who have undergone one to three lines of therapy. Further, the combination provides enhanced flexibility and easiness to the patients.
- Mar-2020: Sanofi announced FDA approved the use of Sarclisa in combination with dexamethasone and pomalidomide. The combination is intended for the treatment of adults with relapsed refractory multiple myeloma (RRMM), who have already received two therapies. The approval provides patients with hard-to-treat multiple myeloma with a new treatment option.
Scope of the Study
By End-user
- Hospitals
- Clinics
- Others
By Disease Type
- Active Multiple Myeloma
- Smoldering Multiple Myeloma
By Drug Type
- Protease Inhibitors
- Monoclonal Antibody
- Chemotherapy
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Global Multiple Myeloma Market by End User
Chapter 5. Global Multiple Myeloma Market by Disease Type
Chapter 6. Global Multiple Myeloma Market by Drug Type
Chapter 7. Global Multiple Myeloma Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Methodology
LOADING...
